Sankar D Navaneethan1, Sreedhar Mandayam2, Susana Arrigain3, Mahboob Rahman4, Wolfgang C Winkelmayer2, Jesse D Schold5. 1. Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX; Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX. Electronic address: sankar.navaneethan@bcm.edu. 2. Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX. 3. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH. 4. Department of Nephrology, Case Western Reserve University, University Hospitals Case Medical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH. 5. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Abstract
BACKGROUND: Prevalence and factors associated with obstructive and restrictive lung function in people with chronic kidney disease (CKD) are unknown. STUDY DESIGN: Cross-sectional and longitudinal analyses. SETTING & PARTICIPANTS: Participants aged 40 to 79 years from NHANES (National Health and Nutrition Examination Survey) 2007 to 2012 who underwent spirometry testing. PREDICTOR: CKD (estimated glomerular filtration rate [eGFR] >15-<60mL/min/1.73m(2) or urinary albumin-creatinine ratio ≥ 30mg/g). OUTCOMES: Restrictive lung function (defined as FEV1/FVC≥0.70 and baseline FVC<80% predicted), obstructive lung function (defined as FEV1/FVC<0.70 based on postbronchodilator spirometric results), and mortality data (available for 2007-2008 and 2009-2010 survey periods). RESULTS: 7,610 participants (CKD=1,338; non-CKD=6,272) were included. Prevalences of obstructive lung function adjusted to the mean age of 55 years and 50% men in the CKD and non-CKD groups were 15.6% and 13.3%, respectively (P=0.2). Similarly, adjusted prevalences of restrictive lung function in the CKD and non-CKD groups were 9.8% and 6.7%, respectively (P=0.01). Presence of albumin-creatinine ratio ≥ 30mg/g was associated with obstructive (OR, 1.42; 95% CI, 1.07-1.88) and restrictive lung function (OR, 1.43; 95% CI, 1.01-2.03) in the entire study cohort. eGFR<60mL/min/1.73m(2) was associated with higher odds of obstructive lung function. In a multivariable Cox model, age (HR, 1.07; 95% CI, 1.04-1.11) and presence of obstructive lung function (HR, 2.68; 95% CI, 1.80-3.97), but not CKD measures, were associated with death. LIMITATIONS: Small proportion of participants with advanced kidney disease. CONCLUSIONS: In a representative sample of US adults, impaired lung function is common in those with and without CKD. Albuminuria was independently associated with both obstructive and restrictive lung function, and eGFR<60mL/min/1.73m(2) was associated with higher odds of obstructive lung function. Older age and obstructive lung function were associated with higher likelihood of death. Further studies examining the burden of lung disease in advanced CKD are needed.
BACKGROUND: Prevalence and factors associated with obstructive and restrictive lung function in people with chronic kidney disease (CKD) are unknown. STUDY DESIGN: Cross-sectional and longitudinal analyses. SETTING & PARTICIPANTS: Participants aged 40 to 79 years from NHANES (National Health and Nutrition Examination Survey) 2007 to 2012 who underwent spirometry testing. PREDICTOR: CKD (estimated glomerular filtration rate [eGFR] >15-<60mL/min/1.73m(2) or urinary albumin-creatinine ratio ≥ 30mg/g). OUTCOMES: Restrictive lung function (defined as FEV1/FVC≥0.70 and baseline FVC<80% predicted), obstructive lung function (defined as FEV1/FVC<0.70 based on postbronchodilator spirometric results), and mortality data (available for 2007-2008 and 2009-2010 survey periods). RESULTS: 7,610 participants (CKD=1,338; non-CKD=6,272) were included. Prevalences of obstructive lung function adjusted to the mean age of 55 years and 50% men in the CKD and non-CKD groups were 15.6% and 13.3%, respectively (P=0.2). Similarly, adjusted prevalences of restrictive lung function in the CKD and non-CKD groups were 9.8% and 6.7%, respectively (P=0.01). Presence of albumin-creatinine ratio ≥ 30mg/g was associated with obstructive (OR, 1.42; 95% CI, 1.07-1.88) and restrictive lung function (OR, 1.43; 95% CI, 1.01-2.03) in the entire study cohort. eGFR<60mL/min/1.73m(2) was associated with higher odds of obstructive lung function. In a multivariable Cox model, age (HR, 1.07; 95% CI, 1.04-1.11) and presence of obstructive lung function (HR, 2.68; 95% CI, 1.80-3.97), but not CKD measures, were associated with death. LIMITATIONS: Small proportion of participants with advanced kidney disease. CONCLUSIONS: In a representative sample of US adults, impaired lung function is common in those with and without CKD. Albuminuria was independently associated with both obstructive and restrictive lung function, and eGFR<60mL/min/1.73m(2) was associated with higher odds of obstructive lung function. Older age and obstructive lung function were associated with higher likelihood of death. Further studies examining the burden of lung disease in advanced CKD are needed.
Authors: Carlos A Vaz Fragoso; Gail McAvay; Peter H Van Ness; Richard Casaburi; Robert L Jensen; Neil MacIntyre; Thomas M Gill; H Klar Yaggi; John Concato Journal: Am J Respir Crit Care Med Date: 2015-10-01 Impact factor: 21.405
Authors: Earl S Ford; David M Mannino; Anne G Wheaton; Wayne H Giles; Letitia Presley-Cantrell; Janet B Croft Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Anne G Wheaton; Earl S Ford; William W Thompson; Kurt J Greenlund; Letitia R Presley-Cantrell; Janet B Croft Journal: BMC Public Health Date: 2013-09-17 Impact factor: 3.295
Authors: Carmine Zoccali; Raymond Vanholder; Ziad A Massy; Alberto Ortiz; Pantelis Sarafidis; Friedo W Dekker; Danilo Fliser; Denis Fouque; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Gianfranco Parati; Patrick Rossignol; Andrzej Wiecek; Gerard London Journal: Nat Rev Nephrol Date: 2017-04-24 Impact factor: 28.314
Authors: Emily S Wan; John E Hokanson; Elizabeth A Regan; Kendra A Young; Barry J Make; Dawn L DeMeo; Stefanie E Mason; Raul San Jose Estepar; James D Crapo; Edwin K Silverman Journal: Chest Date: 2021-09-27 Impact factor: 9.410
Authors: Emily S Wan; Pallavi Balte; Joseph E Schwartz; Surya P Bhatt; Patricia A Cassano; David Couper; Martha L Daviglus; Mark T Dransfield; Sina A Gharib; David R Jacobs; Ravi Kalhan; Stephanie J London; Ana Navas-Acien; George T O'Connor; Jason L Sanders; Benjamin M Smith; Wendy White; Sachin Yende; Elizabeth C Oelsner Journal: JAMA Date: 2021-12-14 Impact factor: 157.335
Authors: Sankar D Navaneethan; Carl P Walther; L Parker Gregg; Shweta Bansal; Wolfgang C Winkelmayer; Vijay Nambi; Jingbo Niu Journal: Am J Kidney Dis Date: 2021-04-24 Impact factor: 8.860